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ABSTRACT: We report the results of a binding free energy-based virtual
screening campaign of a library of 77 α-hydroxytropolone derivatives
against the challenging RNase H active site of the reverse transcriptase
(RT) enzyme of human immunodeficiency virus-1. Multiple protonation
states, rotamer states, and binding modalities of each compound were
individually evaluated. The work involved more than 300 individual
absolute alchemical binding free energy parallel molecular dynamics
calculations and over 1 million CPU hours on national computing clusters
and a local campus computational grid. The thermodynamic and
structural measures obtained in this work rationalize a series of
characteristics of this system useful for guiding future synthetic and
biochemical efforts. The free energy model identified key ligand-
dependent entropic and conformational reorganization processes difficult
to capture using standard docking and scoring approaches. Binding free
energy-based optimization of the lead compounds emerging from the virtual screen has yielded four compounds with very
favorable binding properties, which will be the subject of further experimental investigations. This work is one of the few reported
applications of advanced-binding free energy models to large-scale virtual screening and optimization projects. It further
demonstrates that, with suitable algorithms and automation, advanced-binding free energy models can have a useful role in early-
stage drug-discovery programs.
■ INTRODUCTION
It is very challenging to design potent and specific drugs for
clinical use. The chemical synthesis of specific derivatives to
probe binding preferences is often the most involved and time-
consuming process. Information from experimental structures
of receptor−inhibitor complexes, when available, is often an
invaluable resource to guide the chemical synthesis efforts
toward the most promising leads. Often, however, crystallo-
graphic data are limited to a very small fraction of chemical
space and biological conditions. The design of human
immunodeficiency virus (HIV)-1 RNase H inhibitors is a
particularly difficult medicinal chemistry problem. The RNase
H domain of the reverse transcriptase (RT) catalyzes the
degradation of the DNA/RNA hybrid formed during the RT
process.1 Inhibition of this functionality of HIV RT prevents
viral replication.2 However, despite substantial efforts,3−11 to
this date there have been no clinically approved drugs that
target the RNase H domain of RT. This is in contrast to the
widely available nucleoside reverse transcriptase inhibitors12,13
and integrase strand transfer inhibitors,10,14,15 which target two-
metal catalyzed nuclease functionalities similar to that of RNase
H.
There is likely a fundamental biophysical basis for the lack of
progress. The HIV RNase H active site is rather shallow and
offers few specific structural anchors to exploit.4,16 Compared
to polymerization and integrase inhibitors, with half maximal
inhibitory concentrations (IC50’s) in the low nanomolar range,
even the best RNase H inhibitors display relatively weak and
nonspecific binding. The lack of specificity in turn causes
toxicity due to unwanted binding to the structurally similar
human RNase H and to other cellular enzymes. Lack of
thorough structural and mechanistic understanding of the
function of RNase H in the cellular context also poses
additional challenges. For example, the effect of the RNA/DNA
substrate on inhibitor binding is complex and poorly under-
stood. Often RNase H inhibitors with promising in vitro
characteristics do not display effective viral neutralization
capacity when tested in vivo.17,18
Structure-based computer-aided drug design has become
standard practice in drug-discovery programs in academia and
industry. The fundamental idea is to use available crystallo-
graphic models to predict computationally the strength of
binding of ligands to protein receptors to guide synthetic,
biochemical, and medicinal efforts. Most often computational
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modeling in this area is in the form of high-throughput virtual
screens using fast docking and scoring methods capable of
processing ligand libraries containing thousands of ligands.19−23
Docking and scoring methods are particularly successful in
screening out ligands unlikely to bind due to steric and
energetic incompatibility and in providing structural models of
the receptor−ligand complexes. They are, however, often
unsuitable for accurate ranking of binders as well as for lead
optimization. These applications are increasingly being
addressed by physics-based methods that seek to directly
compute the binding constant or, equivalently, the free energy
of protein−ligand binding.24 Relative free energy perturbation
protocols aimed at estimating differences of binding free
energies between related compounds have achieved a high level
of reliability and automation.25 Deployment of absolute binding
free energy models within drug-discovery programs26−32 is far
less common. These are applicable to ligand libraries containing
diverse scaffolds that are not amenable to relative binding free
energy approaches. They are also suitable for comparative
studies of binding to multiple receptors to, for instance,
enhance specificity. From a biophysical point of view, the main
advantage of binding free energy models is their ability to
represent entropic and reorganization effects that oppose
binding. We have shown for example that free energy models
can improve screening enrichment of focused ligand
libraries.32,33
In this work, we investigate computationally the binding of a
library of α-hydroxytropolones (Figure 1),34 a promising class
of RNase H inhibitors,17,18,35 by means of free energy modeling
using the binding energy distribution analysis method
(BEDAM) and advanced parallel molecular dynamics con-
formational sampling. The best synthetic α-hydroxytropolones
characterized so far have exhibited in vitro potencies in the
hundreds of nanometers range and a reasonable therapeutic
window in cell-based antiviral assays. However, biochemical
inhibition data collected so far do not show strong structure−
activity relationships (SARs). The RNase H functionality of
HIV-1 RT continues to be the subject of intense investigation
because it is one of the few fundamental biochemical functions
of the virus that is not yet targeted by antiviral drugs. Many
inhibitors of HIV-1 RNase H have been discovered;4,6,36
however, none of them has entered clinical trials due to poor in
vivo activity. α-Hydroxytropolones, chiefly represented by the
parent compound β-thujaplicinol, are observed to non-
competitively bind to the active site of RNase H of HIV-1
RT. β-Thujaplicinol and manicol are two α-hydroxytropolone
natural products, which have shown to potently inhibit HIV-1
RNase H with promising specificity and a favorable therapeutic
window.4,35 The α-hydroxytropolone core offers a convenient
and flexible platform to build a large and diverse library of
inhibitors. Our efforts are aimed at discovering synthetic α-
hydroxytropolone derivatives with increased affinity and
specificity for HIV-1 RNase H, so as to achieve enhanced in
vivo potency. The modeling work reported here is part of an
effort to gain further insight into the physicochemical
properties of the RNase H active site to guide further synthetic
and biochemical investigations toward this goal.18
This work also represents an interdisciplinary experiment
aimed at evaluating the feasibility and usefulness of
incorporating advanced-binding free energy modeling into the
structure-based drug-discovery pipeline. Investigating SAR
exclusively by experimental means, involving the synthesis of
a large variety of derivatives and inferring their effects on
receptor binding by measuring their in vitro and in vivo
activities, is a tedious and expensive process. In addition,
because of the complexities of inhibitory mechanisms, the
relationship between receptor binding and activity is often
unclear. The known structures of the RNase H domain of HIV-
1 in complex with inhibitors, as well as with several α-
hydroxytropolones, can serve as the basis of structure-based
efforts to guide synthetic and biochemical efforts. However,
standard docking and scoring computational approaches to
predict affinities of α-hydroxytropolones have been of limited
usefulness due to lack of discriminatory potential. Compounds
known to have poor affinity are often docked and ranked as
favorably as more potent ones. This is likely due to the shallow
nature of the RNase H active site and subtle conformational
reorganization effects, which affect binding.
Our absolute binding free energy model29,37,38 is particularly
suitable to tackle difficult systems such as this. It fully treats the
thermodynamics of binding including the formation of ligand−
receptor interactions and conformational reorganization
processes. We describe in this work, several cases in which,
Figure 1. Nomenclature of side-chain substituents around the α-
hydroxytropolone core.
Figure 2. Crystal structure (3K2P) of the β-thujaplicinol bound active site of the RNase H (A), and β-thujaplicinol modeled in the corresponding
flipped conformation, obtained by 180° rotation around the ligand axis in the plane of the bound cations (B).
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for example, binding is enhanced by interactions with structural
elements that form with some ligands but not with others.
Conversely, in some cases, intramolecular hydrophobic
interactions adversely affect binding. Representing these
dynamical processes is key to understand binding propensities
in this and other systems. At the same time, our methodology,
because it treats each ligand independently and unlike double-
decoupling methods,39 requires only one thermodynamic
transformation step and is straightforward to setup and deploy
for relatively large ligand libraries. The protocol outlined here
should find general applicability to structure-based drug-
discovery programs.
■ MATERIALS AND METHODS
System Preparation. The computational model of the
RNase H domain of HIV-1 RT was generated from the PDB
crystal structure 3K2P4 with bound β-thujaplicinol (Figure 2).
Receptor preparation (hydrogen atom addition, protonation
state selection, etc.) was carried out with the software “Protein
Preparation Wizard, Schrodinger Suite (2014) LLC, New York,
NY”40 using the optimized potential for liquid simulations
(OPLS) 2005 force field. Modeling of the ligand chelation of
the magnesium cations41 (replaced in the crystal structure by
the corresponding manganese(II) cations) is important as these
play a key role in the ribonuclease function of the enzyme.4 The
metal cations are known not to bind simultaneously to the
binding site in the absence of a bound substrate or inhibitor,4
and the alchemical process (see below) includes the modeling
of the ligand-free state of the receptor. In addition, the
applicability of classical nonpolarizable force fields, such as the
one employed here, to describe interactions between organic
ligands and divalent metal cations is challenging.42,43 Hence, we
opted to impose restraining potentials to the metal cations to
maintain them bound to the active site residues. Specifically,
flat-bottom harmonic potentials centered at 3.0 Å and of
tolerance 2.0 Å were applied to the distance between metal ion
A, which is the one closer to HIS 539, and the Cα atoms of
residues 478, 443, and 498, and between metal “B” and the Cα
atoms of the residues 443, 498, and 549 (metal cations are
labeled as in ref 4).
We selected a virtual library of 77 α-hydroxytropolones (see
Table S1), based on known leads and ongoing synthetic
efforts.17,18 β-Thujaplicinol, a naturally occurring α-hydroxy-
tropolone inhibitor,44 was set as the reference compound for
the computation of relative binding free energies (see below).
The classical force field used here is not suitable to describe
accurately variations in the strength of the interaction between
the ligand and the metal cations. The model employed here is
meant to probe the effects of substitutions away from the metal
chelation groups, assuming that metal chelation modality and
strength do not vary significantly across the ligands in the
library. Consequently, the other known natural α-hydroxy-
tropolone inhibitor, manicol, could not be treated with the
present model, given its unique mode of chelation of the metal
cations.17
Ligand structures were prepared by using the LigPrep
workflow within the Maestro program. The protonation and
tautomerization states were generated at a target pH of 7.0 ±
2.0. The two hydroxyl groups on the tropolone ring, which
contact the metal ions of the receptor, were modeled as
deprotonated.4,34,45 Ionization penalties were calculated at pH
7 with Epik46 and added to the BEDAM results (see below) to
yield protonation state-specific binding free energies. Stereo-
isomers resulting from alkyl nitrogen inversion, rotamers, and
binding poses separated by high energy barriers were modeled
individually, as they do not interconvert during the simulations.
Motivated by the free energy combination expression,31,47 the
predicted binding free energy of a compound was taken as the
most favorable among the ones obtained for all of its
conformers and protonation states considered.
A total of 136 complexes resulting from multiple protonation
states and alternative stereoisomers of the 77 ligands
considered were input into the Glide docking program
(Schrodinger, LLC). Glide receptor grid generation employed
the structure of the receptor prepared as above. The
crystallographic position of β-thujaplicinol in 3K2P was
identified as the center of the docking search region. Positional
constraints and metal coordination constraints were applied to
correctly chelate the ligands with two Mn(II) ions. The
resulting docked conformations of the complexes were used as
initial structures for the binding free energy calculation.
BEDAM Binding Free Energy Protocol. The
BEDAM29,48 is an established protocol for the estimation of
absolute binding free energies of molecular com-
plexes.31,33,49−53 The model employs the analytic generalized
Born plus nonpolar (AGBNP2) implicit representation of the
aqueous solution.37 The standard binding free energy, ΔGAB° , of
a receptor A and a ligand B is expressed as49
Δ ° = − ° + ΔG k T C V GlnAB B site AB (1)
where C° is the standard concentration of ligand molecules (1
M, or, equivalently, 1/(1668 Å3)) and Vsite is the volume of the
binding site. The first term of eq 1, −kBT ln C°Vsite, can be
interpreted as the entropic work related to transfer the ligand
from a solution at concentration C° to the binding site of the
ligand−receptor complex, which depends only on the standard
state and the definition of the complex macrostate and is
independent of specific energetic and structural properties of
the ligand and the receptor. The second term on the right-hand
side of eq 1 is the excess contribution to the binding free
energy. It represents the work to couple a receptor and a ligand,
that is to turn on receptor−ligand interactions, while the ligand
is confined within the binding site region. Formally, the excess
binding free energy is defined as
Δ = − ⟨ ⟩β−G k T ln e u rAB B
( )
0 (2)
where β = 1/kBT, ⟨⟩0 represents an ensemble average in the
artificial state in which the ligand and the receptor are
uncoupled (with the ligand confined within the binding site)
when they interact only with the solvent continuum,29 and r
represents a specified conformation of the complex. In eq 2,
u(r) is the binding energy of the complex in conformation r
defined as
= −u U Ur r r( ) ( ) ( )1 0 (3)
where U1(r) and U0(r) are the effective potential energies of
the complex when the ligand and the receptor are coupled and
uncoupled, respectively.
ΔGAB is evaluated by staged free energy perturbation
54 using
the λ-dependent biasing hybrid potential energy function
λ= +λU U ur r r( ) ( ) ( )0 (4)
where λ is the free energy progress parameter, 0 ≤ λ ≤ 1. ΔGAB
is defined as the free energy difference between the λ = 0 and 1
states of the complex. Other intermediate values of λ trace an
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alchemical thermodynamic path connecting these two states.
Binding energy samples are collected from multiple molecular
dynamic simulations at different values of λ. These are analyzed
using the unbinned weighted histogram analysis method52,55 to
compute the binding free energy, ΔGAB. A soft core binding
energy function31 is introduced to improve the convergence of
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where umax is a large positive value (1000 kcal/mol in this
work). This modified binding energy function replaces the
actual binding energy function (eq 3) wherever it appears, so as
to cap the maximum unfavorable value of the binding energy
while leaving the favorable value of binding energies
unchanged.
The AGBNP2 implicit solvation model was used in this
work. The full description of the AGBNP2 model is available
elsewhere.37 It is based on a geometrical-parameter-free
analytical implementation of the pairwise descreening scheme
of the generalized Born model.56 The AGBNP2 model
estimates the solvation free energy of the solute, ΔGsolv, in
the form of
Δ = Δ + Δ + ΔG G G Gsolv elec np HB (6)
where ΔGelec is the electrostatic contribution, ΔGnp is the
nonpolar contribution, and ΔGHB is a solute−solvent hydrogen
bonding term. The electrostatic term is calculated by means of
a variation of the continuum dielectric Generalized Born
model.57,58 The nonpolar contribution includes cavitation- and
dispersion-free energy terms; the first is modeled by a surface
area model and the second by an expression based on the Born
radius of each atom.58
To accelerate conformational sampling, a biased sampling
and parallel Hamiltonian replica exchange method (HREM)
was employed in this work.29 In this scheme, pairs of simulation
replicas periodically attempt to exchange λ values through a
Monte Carlo λ-swapping move. Despite the use of HREM, we
observed very slow interconversion between conformations of
the ligands related by 180° rotation with respect to the metal
coordination plane (Figure 2). To correct this deficiency in this
work, we have individually considered the two orientations of
the ligand. In this strategy, the binding free energy of each of
the 77 ligands considered was estimated from the results of two
BEDAM simulations, corresponding to the two orientations of
the ligand, for a total of 272 BEDAM simulations. The binding
free energy of the ligand is obtained by combining the BEDAM
results for each conformation, assuming equal populations in
solution of the two orientations.59
Orientations of β-thujaplicinol analogues are classified on the
basis of the crystal structure of β-thujaplicinol in complex with
HIV RNase H (PDB id 3K2P). In this structure, the isopropyl
side chain is on the same side as the “A” metal cation and
proximal to His 539 (Figure 2). For the analogues of β-
thujaplicinol, we define the crystallographic orientation as the
one in which the larger of the R1 and R2 side groups (see
Figure 1) is at the same position as the side group of the
isopropyl side group of β-thujaplicinol in the 3K2P crystal
structure. The opposite orientation is classified as “flipped”.
Examples of crystallographic and flipped conformations for β-
thujaplicinol are shown in Figure 2.
Computational Details. The BEDAM simulations em-
ployed the 2005 version of the OPLS-AA60 force field together
with the AGBNP2 implicit solvent model.37 The force field
parameters were automatically assigned by using Schrödinger’s
atomtyper.61 The parallel alchemical Hamiltonian Replica
Exchange molecular dynamics simulations were conducted
using the Asynchronous Replica Exchange software62 with the
IMPACT MD engine.61 Approximately half of the BEDAM free
energy calculations were conducted on the SuperMIC cluster at
the Louisiana State University as part of the Extreme Science
and Engineering Discovery Environment (XSEDE) NSF
consortium. The other half of calculations were conducted on
the Brooklyn College WEB computational grid, based on the
BOINC grid software. The simulation temperature was set to
be 300 K for all simulations. A total of 18 intermediate
alchemical steps at λ = 0.0, 0.002, 0.004, 0.008, 0.01, 0.02, 0.04,
0.07, 0.1, 0.17, 0.25, 0.35, 0.5, 0.6, 0.7, 0.8, 0.9, and 1.0 were
used to conduct the λ-biased replica exchanges. The binding
site volume was defined as the conformation in which the
center of mass of the ligand was within 5 Å of the center of
mass of the receptor, where the center of mass of the ligand was
calculated including only the atoms of the core structure (C1-
C2-C3-C4-C5-C6-C7). The center of mass of the receptor site
was calculated in terms of the Cα atoms of residues 443, 444,
478, 498, 539, 549, and 557 (RT chain A numbering).63 A flat-
bottom torsional restraint potential in terms of the dihedral
angle between the C1, C6 atoms of the ligand and the Cα atoms
of the residue 478 and 443 was applied to confine the ligand in
one of the two orientations relative to the metal coordination
plane (see above). The simulation system was minimized and
thermalized at 300 K. Bond lengths with hydrogen atoms were
constrained using SHAKE. The mass of hydrogen atoms was
set to be 5 amu. A 12 Å residue-based cutoff was imposed on
both direct and generalized Born pair interactions. BEDAM
calculations were performed for approximately 2.5 ns of MD
simulation per replica (45 ns in total for each complex), starting
from the docked ligand poses. Data from the last 2 ns per
replica was used for free energy analysis. Binding energies were
sampled with a frequency of 1 ps for a total of 18 × 2000 = 36
000 binding energy samples per complex.
■ RESULTS
Binding Free Energy-Based Screening of Ligand
Library. The natural α-hydroxytropolone, β-thujaplicinol, was
simulated starting from the 3K2P crystal structure.4 The crystal
structure of β-thujaplicinol in complex with the RNase H
domain (3K2P) served also as a starting structural model for all
of the complexes with α-hydroxytropolone derivatives consid-
ered here. β-thujaplicinol is known to coordinate two divalent
metal ions at the RNase H active site through its carbonyl and
hydroxyl functional groups.4 In the crystal structure, the
tropolone ring of β-thujaplicinol is approximately coplanar
with the metal cations. The same coplanar conformation is seen
in our molecular dynamics simulations of β-thujaplicinol and its
derivatives in both the orientations considered (Figure 2). The
pattern of interactions between the oxygen atoms of the
tropolone ring and the metal cations is also reproduced. The
isopropyl side group of β-thujaplicinol does not significantly
interact with residues of the RNase H active site. Consequently,
the binding free energy scores for the two binding orientations
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are similar (ΔΔGb° = 0.8 kcal/mol, favoring the flipped
orientation).
The BEDAM estimates of the relative binding free energies
of the 77 analogues of β-thujaplicinol studied here are listed in
Table S1 of the Supporting Information. The results for a
selected set are shown in Table 1. Relative binding free energy
estimates are expressed with respect to the binding free energy
estimate of the flipped orientation of β-thujaplicinol.
Preference for Flipped Binding Orientation. As discussed
above, to thoroughly score all possible binding modes, we
separately evaluated the crystallographic and flipped binding
orientations of each ligand (see Figures 2 and 3). Interestingly,
for most ligands, the flipped orientation yielded a more
favorable binding free energy. For example (see Table 1),
ligand 23 in the crystallographic orientation has a relative
binding free energy of 0.9 kcal/mol compared to −2.0 kcal/mol
Table 1. Computed BEDAM Relative Binding Free Energies, ΔΔGb°, for Selected Inhibitors of HIV-1 RNase H
aSee text for a description of ligand identifiers. bIn kcal/mol. cReference compound. d“Cryst.” refers to the crystallographic orientation, and “flipped”
refers to the flipped orientation.
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for the flipped orientation, a difference of 2.9 kcal/mol favoring
the flipped orientation. Similarly, the flipped orientation of
ligand 26 is favored by 3.8 kcal/mol over the crystallographic
orientation (Table 1). In general, we found that the flipped
orientation is preferred over the crystallographic orientation in
61 of the 77 analogues.
Analysis of the molecular dynamics trajectories reveals that
this behavior is due to the placement of the R2 side group
within the interaction distance with the so-called “500” area64
of the RNase H active site. Illustrative structures for ligand 23
are shown in Figure 3. In the crystallographic orientation
(Figure 3A), the long aromatic R2 substituent of the ligand
does not strongly interact with neighboring residues.
Conversely, in the flipped orientation (Figure 3B), the R2
substituent forms strong hydrophobic interactions with GLN
500 and TYR 501. These interactions stabilize the complex and
lead to a more favorable binding free energy.
The ratio of populations of the two binding poses is equal to
the ratio of the Boltzmann factors of their corresponding
binding free energies.31,59 For example, the calculations predict
that the flipped binding pose of ligand 23 is approximately 190
times more probable than the crystallographic pose. In contrast,
β-thujaplicinol, for which the difference in the binding free
energy between the two orientations is significantly smaller, is
predicted to position in the two orientations with similar
probability. This is consistent with the crystallographic
structures.
Biochemical evidence and SAR analysis suggest that in the
cellular environment, in the presence of the RNA/DNA hybrid
substrate, the flipped binding pose may not be accessible to α-
hydroxytropolones inhibitors.65 It is believed that the substrate,
anchored to the polymerization site65 and the inhibitor, bound
to the RNase H active site, can bind concurrently to the HIV
RT dimer. Furthermore, according to this model, the 3′ end of
Figure 3. Representative structures of the crystallographic (A) and flipped (B) binding poses of ligand 23.
Table 2. Computed BEDAM Relative Binding Free Energies, ΔΔGb°, and Experimental ΔTm and IC50 for Some of the Inhibitors
of RNase H
aSee text for a description of ligand identifiers. bIn kcal/mol. cIn degree. d“Cryst.” refers to the crystallographic orientation. eIn μM.
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the RNA strand covers the 500 region of the RNase H
domain65 and sterically limits the orientation of the inhibitor.
Whenever useful, below we analyze the modeling results for
each orientation of the ligand individually. The significance of
the crystallographic orientation rests on its potential relevance
for in vivo inhibition. The flipped orientation is significant for
its potential to acquire additional inhibition activity by means of
substrate displacement and as a starting point for the design of
more potent and specific inhibitors incorporating DNA
intercalators.66
Effect of R3 Side Group. The most evident SAR emerging
from the binding free energy data is the significantly higher
affinity of compounds substituted at the R3 position. For the
reference compound, β-thujaplicinol, and for most of the
ligands in the library, R3 is hydrogen. In compounds 1 through
5, this position is replaced by methyl and phenyl esters, methyl,
or bromide (Tables 2 and S1). All of these substituents at R3,
although less so for methyl, result in significantly more
favorable binding free energies than β-thujaplicinol (gains as
high as ∼10 kcal/mol) in both the crystallographic and flipped
poses. The improvements in binding free energy is likely
overestimated. Nevertheless, the qualitative trend appears to be
robust based on the structural information gained in the
simulations. In the crystallographic orientation, the substituent
at R3 fits into a side pocket lined by ARG 557, ALA 538, and
HIS 539. Interestingly, we found that ARG 557, which is
normally disordered, in the presence of a substituent at R3
forms a strong solvent-shielded hydrogen bond with one of the
deprotonated hydroxyl groups of the ligand. In addition, see,
for example, Figure 6, this interaction is further strengthened by
hydrophobic interactions between the arginine head group and
the aliphatic end group of the R3 substituent. In the flipped
conformation (see, for example, Figure 7), the R3 substituent
occupies a pocket on the other side of the active site, forming
very stable interactions with TYR 501 and SER 499. Similar
affinity gains are predicted for R3 substitutions applied to the
crystallographic or flipped poses.
Effect of R2 Side Group. The greatest chemical variation in
the ligand library investigated is focused on the size and nature
of the R2 side group. The reference compound, β-thujaplicinol,
has an isopropyl R2 side group. All of the members of the
library, except β-thujaplicinol, have a methyl substituent at R1.
We have investigated mostly aromatic substituents at R2, linked
to the tropolone ring by means of alkyl, aromatic, piperidine,
carbonyl, and amide linkers (Table S1). In contrast to the R3
side group, we have generally observed a weak dependence of
binding affinity on the composition of the R2 group.
The effect of R2 is especially weak and often unfavorable for
the crystallographic binding orientation. About two-thirds of
the compounds unsubstituted at R3 have a worse predicted
binding affinity relative to β-thujaplicinol when in the
crystallographic orientation, and only three compounds (ligand
6, 9, and 13) have a predicted binding free energy gain of 2
kcal/mol or better (the assumed accuracy limit of the
computational model). The best gain is −3.2 kcal/mol achieved
for compound 6 with a methyl ester substituent at R2 (Table
2). This a relatively small gain compared to those for
substitutions at R3, which are as high as 10 kcal/mol. The
best compounds in this category, 6, 9, and 13, have an aromatic
or alkyl side group at R2 joined to the tropolone ring by a
carbonyl linker. We found that in the best binding poses, the
R2 head group makes hydrophobic interactions with ALA 538
and the Cβ of HIS 539. Compound 13, which has a longer R2
side group, makes additional interactions with TRP 535, PRO
537, and less often with LYS 540. These interactions are
possible only when selecting an appropriate rotameric state for
R2. We observed that rotation of the carbonyl linker is highly
restrained (especially when R3 is substituted) and is rarely
observed in the simulations. In a number of these circum-
stances, we have scored various R2 and R3 rotameric states
individually (see below).
Apart from the moderate gains noted above, substitutions at
R2 are predicted to have small or negative effects on affinity
when in the crystallographic orientation. The R2 position
points away from the body of the receptor, so opportunities for
strong ligand−receptor interactions are few. In many cases, the
R2 substituent is found to be mostly solvated and not
contributing significantly to binding. Polar substituents tend
to weakly oppose binding due to partial desolvation. This
negative trend is amplified for charged substituents (for
ammonium-containing groups in particular), for which binding
is predicted to be significantly weak. Larger hydrophobic
groups, except for the case noted, tend to disfavor binding,
likely because of unfavorable desolvation of HIS 539, which is
often seen to be turned away from the binding site.
Interestingly, particularly long R2 groups, such as for ligand
64 (Table S1), are seen to loop around to make contact with
TYR 500 and nearby residues, which are normally within the
interaction distance only when the tropolone ring is in the
flipped pose. However, these interactions are weakened by
intramolecular strain of the R2 side group, as evidenced by the
lack of similar conformations in the unbound conformational
ensemble of the ligand. In other cases, large and flexible
hydrophobic groups form strong intramolecular interactions,
which further disfavor binding (discussed below).
The R2 side group has a greater effect on binding affinity in
the flipped binding pose. R2 side groups containing piperidine
linkers generally lead to poorer activity, especially when the
nitrogen is protonated. This effect does not seem to be directly
related to the piperidine group itself but rather to the
hydrophobic head and greater length of the R2 side group
that contain it. The piperidine group tends to interact with
TYR 501, whereas the hydrophobic head group is forced to
extend into the solvent. With other linkers, nitrogen-containing
aromatic head groups tend to lead to better affinity but only if
not protonated. Ligand 27 (see Table 1), where R2 is a phenyl
linker and a naphthyl head group, is the compound predicted to
have the best affinity among those lacking a R3 substituent. The
R2 side group, in the flipped pose, interacts with GLN 500,
TRP 535, and PRO 537. To do so, the R2 group is required to
assume a specific rotameric state. Ligand 27 has been chosen as
the starting point for focused optimization below. As
exemplified by ligand 20 (see Table S1), in which R2 is a
biphenyl group, interactions of R2 with the 500 region of the
receptor can be established even with relatively rigid moieties.
In this case, it is the tropolone ring that tilts away from the
optimal metal coordination plane to allow optimal positioning
of the R2 group near TYR 501 and GLN 500.
In general, among the ones we considered, the nature of the
R2 side group linker is predicted to be a minor determinant
factor of improved affinity in both the crystallographic and
flipped binding orientations. Ligands 23 and 24, for example,
which differ by the para- or meta-substituted phenyl linker (see
Table 1), have very similar predicted binding free energies
(−2.0 and −2.1 kcal/mol, respectively) in their flipped binding
orientations. Ligands with similar head groups having either
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amide or carbonyl linkers are predicted to bind with similar
strength.
Intramolecular Hydrophobic Interactions Decrease Bind-
ing Affinity. The computational model employed in this work
attempts to take into account the conformational variability of
both the ligand and the receptor. This feature has proven to be
useful in the rationalization of surprising trends in binding
affinities. For example, even though they differ by only one
additional methylene linker group, we predict a large difference
between the binding affinities of ligands 42 and 46 (see Table
1). In this case, and in a few other cases, we observed that,
during the molecular dynamics simulations, intramolecular
interactions develop between side groups of the ligand, which
adversely affect the binding affinity. As illustrated in Figure 4A,
and consistent with its favorable binding free energy, ligand 42
forms favorable interactions with the 500 region of the receptor
through its R2 substituent. Conversely, due to its greater length
and flexibility, the R2 substituent of ligand 46 is found to loop
back to form a strong intramolecular hydrophobic interaction
with the methyl group at the R1 position of the tropolone ring.
Hence, the R2 side group of ligand 46 is not available to
interact favorably with the receptor. In addition, the bulkier
Figure 4. Representative structures of the complexes with ligands 42 (A) and 46 (B). The binding of ligand 46 is disfavored by intramolecular
hydrophobic interactions.
Figure 5. Representative structures of the complexes with ligand 27 (A) and R2-optimized ligand 78 (B).
Table 3. Computed BEDAM Relative Binding Free Energies, ΔΔGb°, for Optimized α-Hydroxytropolone Inhibitors of RNase H
aSee text for a description of ligand identifiers. bIn kcal/mol. c“cryst.” refers to the crystallographic orientation.
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ligand volume shields the highly polar active site from the
solvent, thereby decreasing the effect of favorable dielectric
polarization. Both of these effects contribute to the poor
predicted binding affinity of ligand 46 relative to ligand 42
despite their chemical similarity. Examples such as this
underscore the complexities of molecular interactions and the
difficulties in identifying SARs of general applicability.
Binding Free Energy-Based Virtual Lead Optimiza-
tion. Some of the best compounds emerging from the free
energy-based screening of the library were chosen as the
starting point for the optimization attempts of side groups. We
focused on the optimization of the R2 side group (see Figure 1
for nomenclature of side groups), using ligand 27 as a starting
point (Table 1), and on the R3 side group, using ligand 1 as a
starting point (Table 2).
Optimization of R2 Side Group. Ligand 27 with the benzyl-
naphthyl substituent at the R2 position showed the best affinity
among the 72 members of the library lacking a R3 substituent
(see Figure 5A and Table S1). As for most other ligands in this
class, ligand 27 shows a preference to bind in the flipped
conformation, where the side group forms interactions with
residues proximal to TYR 501. The optimization strategy we
followed consisted therefore in extending the head groups to
the R2 side chain of ligand 27 to form interactions between the
R2 side groups and the residues along the 500 region of the
receptor, hypothesized to play a role in the allosteric inhibition
of RNase H.67 The R2 side group was modified in a sequence
of steps, which included extending it with biphenyl and ethyl
linkers, and derivatizing it with acetyl and dicarbonyl polar
groups to improve solubility and to attempt to form hydrogen
bonds with the TYR 501 and GLN 500 residues. The
optimization results are interesting. The final optimized
inhibitor (ligand 78, see Table 3) does provide better binding
affinity, having a binding free energy of −6.6 versus −4.6 kcal/
mol for ligand 27. From Figure 5B, it can be seen that a π−π
stacking interaction is formed between the head group of TYR
501 and the naphthyl ring; however, no strong hydrogen
bonding is observed between the carbonyl linkers and the
residues along the 500 helix. As expected, the added biphenyl
head group accesses the area of GLN 507 residue, which was
predicted to be a promising binding region for inhibitors.64
Optimization of R3 Side Group. As mentioned above, the
molecular dynamics free energy calculations revealed that
substitutions at the R3 position (ligands 1 through 5) could
induce recruitment of ARG 557 to form strong ionic
interactions with one of the deprotonated hydroxyl of the α-
hydroxytropolone ligand. In the absence of the R3 substituent,
ARG 557 is consistently disordered and does not contribute to
binding. This observation motivated us to consider the R3
position as a useful optimization target.
Of the five ligands in the library with substitutions at R3, we
chose ligand 1 with a methyl ester substituent as a starting point
because of the opportunity of optimization of hydrophobic
interactions with the side chain of ARG 557. Replacing the
methyl ester group with a phenyl-ketone group, which is thin
enough to fit into the groove between ARG 557 and HIS 539
and at the same time has the potential to form π−π interactions
with the head group of ARG 557, increased affinity by
approximately 2.4 kcal/mol. We observed that the resulting
compound (ligand 79 in Table 3) was also able to form
transient interactions with HIS 539. In an attempt to stabilize
the latter interactions, we introduced a second phenyl group in
the ortho position relative to the carbonyl linker. This second
alteration (ligand 81 in Table 3) indeed resulted in the
formation of stable π−π interactions with HIS 539 and
increased the affinity by 2.1 kcal/mol (Figure 8).
It should be noted that ligand 1 and its descendants (ligands
79 and 81) display severely hindered rotation of the ester side
groups at the R2 and R3 positions. Indeed, interconversion
between rotamers may be slow (on the order of hours or more)
so as to be considered separate atropisomer species.68
Rotameric states of these ligands have been simulated
individually, as they do not interconvert during the molecular
dynamics trajectories. In particular, ligand 79 has four
atropisomer-like states, all of which have been simulated and
only one (shown in Figure 6) displaying strong affinity to
RNase H (−10.7 kcal/mol). Only in this particular
conformation, in which the phenyl groups of the R2 and R3
side groups point toward opposite sides of the tropolone ring,
can the ligand effectively engage ARG 557, as described.
Addition of R4 Side Group. As noted above, most ligands in
the library, including those with substitutions at R3, bind more
strongly in the flipped orientation. In the flipped orientation,
the R3 side group is accommodated in a side pocket lined by
GLN 500 and SER 499. Due to steric constraints, this binding
mode is accessible only by some of the atropisomers of the
ligand (see, for example, Figure 7). To probe the benefits of
forming ligand−receptor interactions on both sides of the
tropolone ring, we have tested the possibility of adding
substituents both at R3 and at the symmetric opposite position,
which we named R4, resulting in ligand 80 (Figure 7). In this
ligand, the R3 and R4 symmetric positions are occupied by
Figure 6. Representative structure of the complex with ligand 79. The
HIS 539 and ARG 557 residues are shown in licorice representation.
Figure 7. Representative structure of the complex with ligand 80. The
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phenyl-ketone groups and the R1 and R2 symmetric positions
by methyl groups. The two methyl groups are responsible for
the atropisomerism, as they hinder free rotation around the
carbonyl-tropolone ring. The specific atropisomer capable of
binding has the phenyl groups on opposite sides of the
tropolone ring (Figure 7). The predicted gain of affinity over β-
thujaplicinol is very significant (−16.6 kcal/mol), albeit most
likely overestimated. One of the phenyl-ketone groups is found
in the small pocket lined by GLN 500 and SER 499. Although
this group occupies the general region occupied by the R2
group in the flipped pose, it is far more sterically constrained.
Hence, we predict that strong inhibitors will have asymmetric
R3/R4 substitutions in which one group will be fairly small (a
phenyl-ketone substituent being close to the maximum size),
whereas the other will be able to assume a variety of sizes and
shapes.
■ DISCUSSION
Modeling work in the context of medicinal chemistry
applications,69−71 including RNase H inhibition,3,72 is most
often based on molecular docking and scoring. We have
recently shown that large-scale free energy-based ligand
screening, while computationally more involved, can offer
greater discriminatory potential in challenging cases like the
present.33 Due to the rather feature-less binding site, in this
work, docking scores did not show clear binding trends.
Starting from structures predicted by molecular docking, we
have scored the binding of the ligands in the library by a
binding free energy computational protocol, which yields
relative thermodynamic dissociation constants directly com-
parable, in principle, to experimental measurements.
The greater resolution power of binding free energy models
rests on their capacity to model reorganization and entropic
thermodynamic driving forces not easily accessible by other
means. Reorganization refers to the energetic and thermody-
namic changes that accompany the remodeling of the
conformations of the ligand and the receptor to enable binding.
This process, often referred to as “induced fit” or “conforma-
tional selection”, is characterized by free energy changes caused
by intramolecular strain and entropic losses, that oppose
binding. In addition, as here, the enzyme−ligand complex can
have substantial conformational variability and cannot be fully
described by any single representative conformation. Conven-
tional models of binding based on static structures, which do
not incorporate these thermodynamic signatures, are less likely
to fully discriminate favorable from less favorable chemical
modifications33,53 and are therefore less informative in difficult
cases like the present.
The binding free energy calculations have identified the R3
side group as the most promising handle to achieve high-affinity
binding. The receptor pockets predicted to be occupied by the
R3 groups are not apparent in the crystal structure of RNase H
bound to β-thujaplicinol. When considering the crystallographic
orientation, binding of the R3 group is predicted to critically
depend on the recruitment of ARG 557, which is otherwise
removed from the binding site region. Similarly, placement of
the R3 group in the SER 499-adjacent pocket follows an overall
expansion of this region and repositioning of side chains to
optimize ligand−receptor interactions. The thermodynamic
consequences of these and other key reorganization processes
are taken into account by the model to discriminate favorable
modifications, to be targeted by further investigations, from less
promising ones.
The ligand design opportunities at the R3 position indicated
by the present computational modeling efforts are supported by
the available experimental data. Murelli et al. have measured the
potencies of ligands 1 through 22 in terms of receptor thermal
shift (ΔTm) and IC50 values.18 In that study, it was observed
that, whereas increasing the size of the R1 substituent had
consistently negative effects on activity, substitutions at R3
could accommodate a range of side groups without loss of
affinity. For example ligands 5 and 6 (Table 2), which differ
only in the presence of the bromine atom at R3, have similar
ΔTm and IC50 values (2.48 vs 2.70 °C and 0.13 vs 0.16 μM,
respectively). Ligand 1, which has a bulkier R3 substituent, is as
potent as ligand 5. Hence, both calculations and experiments
indicate that the R3 position can represent a useful handle for
the design of side groups leading to increased potency. The
simulations identified that the R3 side group induces the
formation of a binding groove sandwiched between ARG 557
and HIS 539, the latter being a key participant to the nuclease
function of RNase H. Specific modifications of R3 are predicted
to lock HIS 539 through strong electrostatic and π−π
interactions, as seen, for example, in the optimized ligand 81
(Figure 8). The simulations have also indicated substantial
potential benefits in adding substituents at the symmetric
opposite position to R3 (the position labeled R4 in Figure 1) as
seen, for example, in the optimized ligand 80 (Figure 7). Doing
so accesses a small pocket near the TYR 501 and SER 499
residues. It is unclear whether the pocket is actually available in
the presence of a substrate (see below); nevertheless, it might
be worthwhile to investigate small substituents such as methyl
or bromide at this position.
Crystallographic structures4,7 show that α-hydroxytropo-
lones, similar to other RNase H active site inhibitors,8−10
coordinate the two metal ions with the tropolone ring placed in
the same plane as the metal ions. This configuration is
preserved in the simulations of all of the ligands we
investigated. The metal coordination geometries and the
approximate C2 symmetry of the α-hydroxytropolones allows
for two distinct binding modes, related by a 180° rotation
(Figure 2), which were individually investigated for each ligand.
In general, stronger affinity was obtained when the ligand was
flipped relative to the crystal structure of β-thujaplicinol and
manicol. When considering the flipped binding orientation,
many ligands in the library are predicted to bind better than the
reference compound (β-thujaplicinol). This is in contrast to the
recently acquired experimental inhibition data on 22 of the 77
ligands investigated here,18 which showed relatively small
Figure 8. Representative structure of the complex with ligand 81. The
HIS 539 and ARG 557 residues are shown in licorice representation.
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variations in potency which were for the most part unfavorable
relative to β-thujaplicinol. The observed binding trends are
reproduced when flipped binding modes are excluded from the
computational model. When both binding orientations are
considered, a majority of ligands are predicted to bind
significantly better than β-thujaplicinol (17 out of 22 with a
−2 kcal/mol cutoff, see Table S1). When, however, only the
crystallographic orientation is considered, the range of binding
free energies is substantially reduced, and only eight ligands
show significantly better binding than β-thujaplicinol. Overall,
these comparative data suggest that, under the conditions of the
experimental inhibition assay, the flipped conformation is not
available to the inhibitors.
The computational model does not take into account the
nucleic acid substrate present in the inhibition assay. It is
known35 that β-thujaplicinol displays noncompetitive inhibitory
behavior consistent with the hypothesis that an inhibitor and a
substrate can bind the enzyme at the same time, possibly
forming direct interactions, as for example in the homology
model shown in Figure 9. This structural model is consistent
with the observation that modifications at the R1 position are
severely limited sterically and that modifications at R2 (more
removed from the assumed position of the substrate) are also
sterically disfavored but to a smaller extent.18 According to this
structural model, the flipped binding mode is not accessible by
the ligands, as it would cause clashes with the substrate. Hence,
the computational data obtained here, which are consistent
with experimental evidence only when the flipped binding
mode is ruled out, further support the model that displacement
of the nucleic acid substrate from the active site does not cause
dissociation of the substrate, which remains in the proximity of
the RNase H active site. The model also explains why
substitutions at the R3 position, which is the farthest from
the substrate, can accommodate a larger variety of side groups.
The evidence collected here suggests that inhibitor design
strategies would benefit from taking into account interactions
with the substrate, and that inclusion of the nucleic acid
substrate in computational models would lead to more reliable
computational predictions.
■ CONCLUSIONS
In this work, we have conducted a large-scale binding free
energy-based virtual screening campaign of a library of 77 α-
hydroxytropolone derivatives against the active site of the
RNase H active site of the RT enzyme of HIV-1. Lead
compounds emerging from the screening process were
subjected to targeted optimization, which resulted in the
identification of compounds with significantly increased
potency. The work involved 280 individual absolute binding
free energy calculations when multiple protonation states,
multiple binding modes, and individual rotamer states of each
ligand were considered. The computational effort for this work
(over 1 million aggregate CPU hours) has been made feasible
by automated protocols and the use of heterogeneous high
performance computing resources at XSEDE and the WEB
computational grid at Brooklyn College. The thermodynamic
and structural measures obtained in this work rationalize a
series of characteristics of this system useful for guiding future
synthetic and biochemical efforts. Specifically, our calculations
support the model that the nucleic acid substrate limits the
range of binding modes available to the inhibitors and that it
likely plays other key roles in the recruitment of inhibitors to
the active site. The computational model further confirms that
small or rigid side groups at R2, which point mostly to the
solvent, have minor effects on affinity. On the other hand,
larger and more flexible R2 side groups can lead to
intramolecular hydrophobic interactions, which significantly
decrease affinity. Substitutions at the R3 position emerge as
more promising. Specific side groups here can have the effect of
recruiting ARG 557 (which is otherwise disordered) to form a
hydrophobically shielded ionic interaction with the ligand.
Further targeted modifications at R3 (exemplified by ligand 81,
Figure 8) are predicted to also induce the recruitment of HIS
539, a key residue involved in the nuclease reaction, forming a
complex stabilized by a network of hydrogen bond, hydro-
phobic and π−π interactions. Future synthetic and biochemical
work will focus on exploiting the ligand design strategies
emerging from this work. Overall, the results presented here
show that modern binding free energy models, when
intelligently integrated into interdisciplinary chemistry efforts,




The Supporting Information is available free of charge on the
ACS Publications website at DOI: 10.1021/acsomega.6b00123.
Chemical structures of the 279 ligand models inves-
tigated, ranked by ligand identification number (ligand-





∥Department of Chemistry, CUNY Brooklyn College, 2900
Bedford Avenue, Brooklyn, New York 11210, United States
(E.G.).
Notes
The authors declare no competing financial interest.
■ ACKNOWLEDGMENTS
E.G. acknowledges support from the National Science
Foundation (SI2-SSE 1440665). R.M. acknowledges support
from the National Institutes of Health (SC1-GM111158).
REMD simulations were carried out on the Supermic cluster of
Figure 9. Homology model of the RNase H domain of HIV-1 RT
(green surface) bound to the RNA/DNA hybrid substrate (blue and
brown ladders) and ligand 1 (blue carbon atoms).
ACS Omega Article
DOI: 10.1021/acsomega.6b00123
ACS Omega 2016, 1, 435−447
445
XSEDE (supported by project TG-MCB150001 to E.G. and
B.Z.) and the WEB computational grid at Brooklyn College of
the City University of New York. The authors acknowledge
invaluable computing support from James Roman and John
Stephen at Brooklyn College.
■ REFERENCES
(1) Sarafianos, S. G.; Marchand, B.; Das, K.; Himmel, D. M.; Parniak,
M. A.; Hughes, S. H.; Arnold, E. J. Mol. Biol. 2009, 385, 693−713.
(2) Tisdale, M.; Schulze, T.; Larder, B. A.; Moelling, K. J. Gen. Virol.
1991, 72, 59−66.
(3) Felts, A. K.; Labarge, K.; Bauman, J. D.; Patel, D. V.; Himmel, D.
M.; Arnold, E.; Parniak, M. A.; Levy, R. M. J. Chem. Inf. Model. 2011,
51, 1986−1998.
(4) Himmel, D. M.; Maegley, K. A.; Pauly, T. A.; Bauman, J. D.; Das,
K.; Dharia, C.; Clark, A. D., Jr.; Ryan, K.; Hickey, M. J.; Love, R. A.;
Hughes, S. H.; Bergqvist, S.; Arnold, E. Structure 2009, 17, 1625−
1635.
(5) Himmel, D.; Sarafianos, S.; Dharmasena, S.; Hossain, M.;
McCoy-Simandle, K.; Ilina, T.; Clark, A., Jr.; Knight, J.; Julias, J.; Clark,
P.; Krogh-Jespersen, K.; Levy, R.; Hughes, S.; Parniak, M.; Arnold, E.
ACS Chem. Biol. 2006, 1, 702−712.
(6) Shaw-Reid, C.; Munshi, V.; Graham, P.; Wolfe, A.; Witmer, M.;
Danzeisen, R.; Olsen, D.; Carroll, S.; Embrey, M.; Wai, J.; Miller, M.;
Cole, J.; Hazuda, D. J. Biol. Chem. 2003, 278, 2777−2780.
(7) Su, H.-P.; Yan, Y.; Prasad, G. S.; Smith, R. F.; Daniels, C. L.;
Abeywickrema, P. D.; Reid, J. C.; Loughran, H. M.; Kornienko, M.;
Sharma, S.; Grobler, J. A.; Xu, B.; Sardana, V.; Allison, T. J.; Williams,
P. D.; Darke, P. L.; Hazuda, D. J.; Munshi, S. J. Virol. 2010, 84, 7625−
7633.
(8) Costi, R.; Met́ifiot, M.; Chung, S.; Crucitti, G. C.; Maddali, K.;
Pescatori, L.; Messore, A.; Madia, V. N.; Pupo, G.; Scipione, L.;
Tortorella, S.; Saverio Di Leva, F.; Cosconati, S.; Marinelli, L.;
Novellino, E.; Le Grice, S. F. J.; Corona, A.; Pommier, Y.; Marchand,
C.; Di Santo, R. J. Med. Chem. 2014, 57, 3223−3234.
(9) Himmel, D. M.; Myshakina, N. S.; Ilina, T.; Van Ry, A.; Ho, W.
C.; Parniak, M. A.; Arnold, E. J. Mol. Biol. 2014, 426, 2617−2631.
(10) Esposito, F.; Tramontano, E. Antiviral Chem. Chemother. 2014,
23, 129−144.
(11) Lansdon, E.; Liu, Q.; Leavitt, S.; Balakrishnan, M.; Perry, J.;
Lancaster-Moyer, C.; Kutty, N.; Liu, X.; Squires, N.; Watkins, W.;
Kirschberg, T. Antimicrob. Agents Chemother. 2011, 55, 2905−2915.
(12) Fowler, B. J.; Gelfand, B. D.; Kim, Y.; Kerur, N.; Tarallo, V.;
Hirano, Y.; Amarnath, S.; Fowler, D. H.; Radwan, M.; Young, M. T.;
Pittman, K.; Kubes, P.; Agarwal, H. K.; Parang, K.; Hinton, D. R.;
Bastos-Carvalho, A.; Li, S.; Yasuma, T.; Mizutani, T.; Yasuma, R.;
Wright, C.; Ambati, J. Science 2014, 346, 1000−1003.
(13) Gallant, J.; Gerondelis, P.; Wainberg, M.; Shulman, N.;
Haubrich, R.; St Clair, M.; Lanier, E.; Hellmann, N.; Richman, D.
Antiviral Ther. 2003, 8, 489−506.
(14) Barreca, M. L.; Ferro, S.; Rao, A.; Luca, L. D.; Zappala,́ M.;
Monforte, A.-M.; Debyser, Z.; Witvrouw, M.; Chimirri, A. J. Med.
Chem. 2005, 48, 7084−7088.
(15) McColl, D.J.; Chen, X. Antiviral Res. 2010, 85, 101−118.
(16) Davies, J.; Hostomska, Z.; Hostomsky, Z.; Jordan, S.; Matthews,
D. Science 1991, 252, 88−95.
(17) Chung, S.; Himmel, D. M.; Jiang, J.-K.; Wojtak, K.; Bauman, J.
D.; Rausch, J. W.; Wilson, J. A.; Beutler, J. A.; Thomas, C. J.; Arnold,
E.; Le Grice, S. F. J. J. Med. Chem. 2011, 54, 4462−4473.
(18) Murelli, R. P.; D’Erasmo, M. P.; Hirsch, D. R.; Meck, C.;
Masaoka, T.; Wilson, J. A.; Zhang, B.; Pal, R. K.; Gallicchio, E.; Beutler,
J. A.; Grice, S. F. J. L. Med. Chem. Commun. 2016, advance article.
(19) Goodsell, D. S.; Morris, G. M.; Olson, A. J. J. Mol. Recognit.
1996, 9, 1−5.
(20) Shoichet, B. K.; McGovern, S. L.; Wei, B.; Irwin, J. J. Curr. Opin.
Chem. Biol. 2002, 6, 439−446.
(21) Forli, S.; Olson, A. J. J. Med. Chem. 2012, 55, 623−638.
(22) Perryman, A. L.; Santiago, D. N.; Forli, S.; Santos-Martins, D.;
Olson, A. J. J. Comput.-Aided Mol. Des. 2014, 28, 429.
(23) Hogues, H.; Sulea, T.; Purisima, E. O. J. Chem. Inf. Model. 2016,
56, 955−964.
(24) Jorgensen, W. L. Science 2004, 303, 1813−1818.
(25) Wang, L.; Wu, Y.; Deng, Y.; Kim, B.; Pierce, L.; Krilov, G.;
Lupyan, D.; Robinson, S.; Dahlgren, M. K.; Greenwood, J.; Romero,
D. L.; Masse, C.; Knight, J. L.; Steinbrecher, T.; Beuming, T.; Damm,
W.; Harder, E.; Sherman, W.; Brewer, M.; Wester, R.; Murcko, M.;
Frye, L.; Farid, R.; Lin, T.; Mobley, D. L.; Jorgensen, W. L.; Berne, B.
J.; Friesner, R. A.; Abel, R. J. Am. Chem. Soc. 2015, 137, 2695−2703.
(26) Boresch, S.; Tettinger, F.; Leitgeb, M.; Karplus, M. J. Phys.
Chem. B 2003, 107, 9535−9551.
(27) Young, T.; Abel, R.; Kim, B.; Berne, B. J.; Friesner, R. A. Proc.
Natl. Acad. Sci. U.S.A. 2007, 104, 808−813.
(28) Zhou, H.-X.; Gilson, M. K. Chem. Rev. 2009, 109, 4092−4107.
(29) Gallicchio, E.; Lapelosa, M.; Levy, R. M. J. Chem. Theory
Comput. 2010, 6, 2961−2977.
(30) Gallicchio, E.; Levy, R. M. Curr. Opin. Struct. Biol. 2011, 21,
161−166.
(31) Gallicchio, E.; Levy, R. M. Adv. Prot. Chem. Struct. Biol. 2011, 85,
27−80.
(32) Gallicchio, E.; Chen, H.; Chen, H.; Fitzgerald, M.; Gao, Y.; He,
P.; Kalyanikar, M.; Kao, C.; Lu, B.; Niu, Y.; Pethe, M.; Zhu, J.; Levy, R.
M. J. Comput.-Aided Mol. Des. 2015, 29, 315−325.
(33) Gallicchio, E.; Deng, N.; He, P.; Perryman, A. L.; Santiago, D.
N.; Forli, S.; Olson, A. J.; Levy, R. M. J. Comput.-Aided Mol. Des. 2014,
28, 475−490.
(34) Piettre, S. R.; Ganzhorn, A.; Hoflack, J.; Islam, K.; Hornsperger,
J.-M. J. Am. Chem. Soc. 1997, 119, 3201−3204.
(35) Budihas, S.; Gorshkova, I.; Gaidamakov, S.; Wamiru, A.; Bona,
M.; Parniak, M.; Crouch, R.; McMahon, J.; Beutler, J.; Le Grice, S.
Nucleic Acids Res. 2005, 33, 1249−1256.
(36) Klumpp, K.; Hang, J. Q.; Rajendran, S.; Yang, Y.; Derosier, A.;
Wong Kai In, P.; Overton, H.; Parkes, K. E. B.; Cammack, N.; Martin,
J. A. Nucleic Acids Res. 2003, 31, 6852−6859.
(37) Gallicchio, E.; Paris, K.; Levy, R. M. J. Chem. Theory Comput.
2009, 5, 2544−2564.
(38) Gallicchio, E.; Levy, R. M.; Parashar, M. J. Comput. Chem. 2008,
29, 788−794.
(39) Hamelberg, D.; McCammon, J. A. J. Am. Chem. Soc. 2004, 126,
7683−7689.
(40) Madhavi Sastry, G.; Adzhigirey, M.; Day, T.; Annabhimoju, R.;
Sherman, W. J. Comput.-Aided Mol. Des. 2013, 27, 221−234.
(41) Poongavanam, V.; Steinmann, C.; Kongsted, J. PLoS One 2014,
9, e98659.
(42) Zhao, H.; Lin, Z.; Lynn, A. Y.; Varnado, B.; Beutler, J. A.;
Murelli, R. P.; Grice, S. F. J. L.; Tang, L. Nucleic Acids Res. 2015, 43,
11003−11016.
(43) Li, P.; Song, L. F.; Kenneth, M.; Merz, J. J. Phys. Chem. B 2015,
119, 883−895.
(44) Gardner, J.; Baron, G.; MacLean, H. Can. J. Chem. 1957, 35,
1039−1048.
(45) Martin, S. F.; Follows, B. C.; Hergenrother, P. J.; Franklin, C. L.
J. Org. Chem. 2000, 65, 4509−4514.
(46) Greenwood, J. R.; Calkins, D.; Sullivan, A. P.; Shelley, J. C. J.
Comput.-Aided Mol. Des. 2010, 24, 591−604.
(47) Mobley, D. L.; Chodera, J. D.; Dill, K. A. J. Chem. Phys. 2006,
125, No. 084902, DOI: 10.1063/1.2221683.
(48) Lapelosa, M.; Gallicchio, E.; Levy, R. M. J. Chem. Theory
Comput. 2012, 8, 47−60.
(49) Gilson, M. K.; Given, J. A.; Bush, B. L.; McCammon, J. A.
Biophys. J. 1997, 72, 1047−1069.
(50) Gallicchio, E.; Levy, R. M. J. Comput.-Aided Mol. Des. 2012, 26,
505−516.
(51) Gallicchio, E. Comput. Mol. Biosci. 2012, 2, 7−22.
(52) Tan, Z.; Gallicchio, E.; Lapelosa, M.; Levy, R. M. J. Chem. Phys.
2012, 136, No. 144102, DOI: 10.1063/1.3701175.
ACS Omega Article
DOI: 10.1021/acsomega.6b00123
ACS Omega 2016, 1, 435−447
446
(53) Wickstrom, L.; He, P.; Gallicchio, E.; Levy, R. M. J. Chem.
Theory Comput. 2013, 9, 3136−3150.
(54) Pohorille, A.; Jarzynski, C.; Chipot, C. J. Phys. Chem. B 2010,
114, 10235−10253.
(55) Shirts, M. R.; Chodera, J. D. J. Chem. Phys. 2008, 129,
No. 124105, DOI: 10.1063/1.2978177.
(56) Feig, M.; Brooks, C. Curr. Opin. Struct. Biol. 2004, 14, 217−224.
(57) Qiu, D.; Shenkin, P. S.; Hollinger, F. P.; Still, C. W. J. Phys.
Chem. A 1997, 101, 3005−3014.
(58) Gallicchio, E.; Levy, R. J. Comput. Chem. 2004, 25, 479−499.
(59) Mobley, D. L.; Dill, K. A. Structure 2009, 17, 489−498.
(60) Kaminski, G. A.; Friesner, R. A.; Tirado-Rives, J.; Jorgensen, W.
L. J. Phys. Chem. B 2001, 105, 6474−6487.
(61) Banks, J.; Beard, J.; Cao, Y.; Cho, A.; Damm, W.; Farid, R.; Felts,
A.; Halgren, T.; Mainz, D.; Maple, J.; Murphy, R.; Philipp, D.;
Repasky, M.; Zhang, L.; Berne, B.; Friesner, R.; Gallicchio, E.; Levy, R.
J. Comput. Chem. 2005, 26, 1752−1780.
(62) Gallicchio, E.; Xia, J.; Flynn, W. F.; Zhang, B.; Samlalsingh, S.;
Mentes, A.; Levy, R. M. Comput. Phys. Commun. 2015, 196, 236−246.
(63) Sarafianos, S. G.; Das, K.; Tantillo, C.; Clark, A. D.; Ding, J.;
Whitcomb, J. M.; Boyer, P. L.; Hughes, S. H.; Arnold, E. EMBO J.
2001, 20, 1449−1461.
(64) Bauman, J. D.; Patel, D.; Dharia, C.; Fromer, M. W.; Ahmed, S.;
Frenkel, Y.; Vijayan, R. S. K.; Eck, J. T.; Ho, W. C.; Das, K.; Shatkin, A.
J.; Arnold, E. J. Med. Chem. 2013, 56, 2738−2746.
(65) Lapkouski, M.; Tian, L.; Miller, J. T.; Le Grice, S. F.; Yang, W.
Nat. Struct. Mol. Biol. 2013, 20, 230−236.
(66) Biebricher, A. S.; Heller, I.; Roijmans, R. F. H.; Hoekstra, T. P.;
Peterman, E. J. G.; Wuite, G. J. L. Nat. Commun. 2015, 6, 7304.
(67) Christen, M. T.; Menon, L.; Myshakina, N. S.; Ahn, J.; Parniak,
M. A.; Ishima, R. Chem. Biol. Drug Des. 2012, 80, 706−716.
(68) Gustafson, J. L.; Lim, D.; Miller, S. J. Science 2010, 328, 1251−
1255.
(69) Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.;
Klicic, J. J.; Mainz, D. T.; Repasky, M. P.; Knoll, E. H.; Shelley, M.;
Perry, J. K.; Shaw, D. E.; Francis, P.; Shenkin, P. S. J. Med. Chem. 2004,
47, 1739−1749.
(70) Cosconati, S.; Forli, S.; Perryman, A. L.; Harris, R.; Goodsell, D.
S.; Olson, A. J. Expert Opin. Drug Discovery 2010, 5, 597−607.
(71) Singh, N.; Warshel, A. Proteins 2010, 78, 1705−1723.




ACS Omega 2016, 1, 435−447
447
